| scholarly article | Q13442814 |
| P50 | author | Paulus Kirchhof | Q38326091 |
| P2093 | author name string | Katrina Mountfort, Medical Writer, Radcliffe Cardiology | |
| P2860 | cites work | Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation | Q44480000 |
| Oral anticoagulation in surgical procedures: risks and recommendations | Q44655411 | ||
| Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. | Q51175352 | ||
| Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. | Q51328729 | ||
| Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Q56620375 | ||
| Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease | Q57260375 | ||
| Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Fac | Q57313032 | ||
| Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment | Q57313061 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion | Q83104350 | ||
| Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry | Q83391897 | ||
| Interpretation of point-of-care INR results in patients treated with dabigatran | Q83393050 | ||
| Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice | Q83409327 | ||
| In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban | Q83942064 | ||
| Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients | Q84813130 | ||
| Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention | Q84897051 | ||
| ??? | Q22242895 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association | Q29614695 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial | Q34624280 | ||
| European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation | Q34651051 | ||
| A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation | Q36203602 | ||
| Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents | Q37897674 | ||
| Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. | Q38474029 | ||
| Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects | Q41904888 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42874726 | ||
| Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study | Q43137255 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| P433 | issue | 2 | |
| P921 | main subject | atrial fibrillation | Q815819 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 115-119 | |
| P577 | publication date | 2013-11-29 | |
| P1433 | published in | Arrhythmia & electrophysiology review | Q27727082 |
| P1476 | title | The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary | |
| P478 | volume | 2 |
Search more.